A 32-year-old woman undergoing chemotherapy for breast cancer (doxorubicin + cyclophosphamide) presents to the oncology clinic for her second cycle. During the first cycle, she experienced severe nausea and vomiting despite receiving ondansetron 8 mg IV before treatment. Her oncologist decides to add a second antiemetic agent to improve control. Which of the following is the most appropriate addition based on mechanism of action?

## Rationale for Combination Antiemetic Therapy **Key Point:** Highly emetogenic chemotherapy (HEC) like doxorubicin + cyclophosphamide requires multimodal antiemetic prophylaxis targeting different receptor pathways simultaneously. ### Mechanism of Chemotherapy-Induced Nausea and Vomiting (CINV) Chemotherapy triggers CINV through: 1. **Acute phase** (0–24 hrs): Release of serotonin (5-HT) from gut enterochromaffin cells → activation of 5-HT~3~ receptors on vagal afferents 2. **Delayed phase** (24–120 hrs): Substance P release → activation of NK~1~ receptors in chemoreceptor trigger zone 3. **Anticipatory phase**: Psychological/conditioned response ### Why Dexamethasone Is the Best Addition | Agent | Class | Primary Target | Best Use | Limitation | |-------|-------|---|---|---| | **Ondansetron** | 5-HT~3~ antagonist | Acute CINV | Excellent for acute phase | Poor delayed CINV control | | **Dexamethasone** | Corticosteroid | NK~1~ pathway + other mediators | **Delayed CINV** | Hyperglycemia, insomnia | | Metoclopramide | D~2~ antagonist | Gastric motility | Gastroesophageal reflux | Weak antiemetic; tardive dyskinesia risk | | Diphenhydramine | H~1~ antagonist | Histamine receptors | Vestibular nausea | Sedation; minimal CINV benefit | | Domperidone | D~2~ antagonist (peripheral) | Gastric motility | Reflux-related nausea | Does not cross BBB; minimal CINV effect | **High-Yield:** NCCN/ASCO guidelines recommend **5-HT~3~ antagonist + corticosteroid ± NK~1~ antagonist** for HEC. Dexamethasone covers the delayed phase (days 2–5) when ondansetron efficacy wanes. **Clinical Pearl:** Dexamethasone is given on days 2–4 post-chemotherapy (not day 1, when acute 5-HT~3~ effects dominate). This sequential targeting of different phases is the hallmark of modern CINV management. ### Dosing Example - Day 1: Ondansetron 8 mg IV + dexamethasone 8 mg IV - Days 2–4: Dexamethasone 8 mg PO daily [cite:KD Tripathi 8e Ch 16]